85 related articles for article (PubMed ID: 27341835)
1. Genomic integration occurs in the packaging cell via unexported lentiviral precursors.
Mosabbir AA; Truong K
Biotechnol Lett; 2016 Oct; 38(10):1715-21. PubMed ID: 27341835
[TBL] [Abstract][Full Text] [Related]
2. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
3. A new-generation stable inducible packaging cell line for lentiviral vectors.
Farson D; Witt R; McGuinness R; Dull T; Kelly M; Song J; Radeke R; Bukovsky A; Consiglio A; Naldini L
Hum Gene Ther; 2001 May; 12(8):981-97. PubMed ID: 11387062
[TBL] [Abstract][Full Text] [Related]
4. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
[TBL] [Abstract][Full Text] [Related]
5. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines.
Stewart HJ; Leroux-Carlucci MA; Sion CJ; Mitrophanous KA; Radcliffe PA
Gene Ther; 2009 Jun; 16(6):805-14. PubMed ID: 19262613
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel trans-lentiviral vector that affords predictable safety.
Wu X; Wakefield JK; Liu H; Xiao H; Kralovics R; Prchal JT; Kappes JC
Mol Ther; 2000 Jul; 2(1):47-55. PubMed ID: 10899827
[TBL] [Abstract][Full Text] [Related]
7. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors.
Wagner R; Graf M; Bieler K; Wolf H; Grunwald T; Foley P; Uberla K
Hum Gene Ther; 2000 Nov; 11(17):2403-13. PubMed ID: 11096444
[TBL] [Abstract][Full Text] [Related]
8. RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.
Stornaiuolo A; Piovani BM; Bossi S; Zucchelli E; Corna S; Salvatori F; Mavilio F; Bordignon C; Rizzardi GP; Bovolenta C
Hum Gene Ther Methods; 2013 Aug; 24(4):228-40. PubMed ID: 23767932
[TBL] [Abstract][Full Text] [Related]
9. Helper plasmids for production of HIV-1-derived vectors.
Fuller M; Anson DS
Hum Gene Ther; 2001 Nov; 12(17):2081-93. PubMed ID: 11747598
[TBL] [Abstract][Full Text] [Related]
10. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
Cockrell AS; Ma H; Fu K; McCown TJ; Kafri T
Mol Ther; 2006 Aug; 14(2):276-84. PubMed ID: 16516556
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions.
ter Brake O; Berkhout B
J Gene Med; 2007 Sep; 9(9):743-50. PubMed ID: 17628029
[TBL] [Abstract][Full Text] [Related]
12. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.
Sparacio S; Pfeiffer T; Schaal H; Bosch V
Mol Ther; 2001 Apr; 3(4):602-12. PubMed ID: 11319923
[TBL] [Abstract][Full Text] [Related]
13. Analysis of lenti- and trans-lentiviral vector genetic recombination.
Wu X; Wakefield JK; Liu H; Kappes JC
Dev Biol (Basel); 2001; 106():237-48; discussion 249, 253-63. PubMed ID: 11761237
[TBL] [Abstract][Full Text] [Related]
14. A stable system for the high-titer production of multiply attenuated lentiviral vectors.
Klages N; Zufferey R; Trono D
Mol Ther; 2000 Aug; 2(2):170-6. PubMed ID: 10947945
[TBL] [Abstract][Full Text] [Related]
15. A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct.
Molina RP; Ye HQ; Brady J; Zhang J; Zimmerman H; Kaleko M; Luo T
Hum Gene Ther; 2004 Sep; 15(9):865-77. PubMed ID: 15353041
[TBL] [Abstract][Full Text] [Related]
16. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture.
Broussau S; Jabbour N; Lachapelle G; Durocher Y; Tom R; Transfiguracion J; Gilbert R; Massie B
Mol Ther; 2008 Mar; 16(3):500-7. PubMed ID: 18180776
[TBL] [Abstract][Full Text] [Related]
17. Continuous high-titer HIV-1 vector production.
Ikeda Y; Takeuchi Y; Martin F; Cosset FL; Mitrophanous K; Collins M
Nat Biotechnol; 2003 May; 21(5):569-72. PubMed ID: 12679787
[TBL] [Abstract][Full Text] [Related]
18. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
[TBL] [Abstract][Full Text] [Related]
19. Design of a trans protease lentiviral packaging system that produces high titer virus.
Westerman KA; Ao Z; Cohen EA; Leboulch P
Retrovirology; 2007 Dec; 4():96. PubMed ID: 18163907
[TBL] [Abstract][Full Text] [Related]
20. Construction of stable packaging cell lines for clinical lentiviral vector production.
Sanber KS; Knight SB; Stephen SL; Bailey R; Escors D; Minshull J; Santilli G; Thrasher AJ; Collins MK; Takeuchi Y
Sci Rep; 2015 Mar; 5():9021. PubMed ID: 25762005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
